375 related articles for article (PubMed ID: 14633739)
1. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
2. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
3. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
4. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.
Chiang HC; Wang CY; Lee HL; Tsou TC
Toxicol Appl Pharmacol; 2011 Jun; 253(2):145-52. PubMed ID: 21473878
[TBL] [Abstract][Full Text] [Related]
7. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen.
He XY; Shen J; Ding X; Lu AY; Hong JY
Drug Metab Dispos; 2004 Dec; 32(12):1516-21. PubMed ID: 15333516
[TBL] [Abstract][Full Text] [Related]
8. Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.
Megaraj V; Zhou X; Xie F; Liu Z; Yang W; Ding X
Carcinogenesis; 2014 Jan; 35(1):131-7. PubMed ID: 23917075
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.
D'Agostino J; Zhang X; Wu H; Ling G; Wang S; Zhang QY; Liu F; Ding X
Drug Metab Dispos; 2008 Nov; 36(11):2316-23. PubMed ID: 18669584
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
Ariyoshi N; Miyamoto M; Umetsu Y; Kunitoh H; Dosaka-Akita H; Sawamura Y; Yokota J; Nemoto N; Sato K; Kamataki T
Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):890-4. PubMed ID: 12223434
[TBL] [Abstract][Full Text] [Related]
11. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population.
Tan W; Chen GF; Xing DY; Song CY; Kadlubar FF; Lin DX
Int J Cancer; 2001 Mar; 95(2):96-101. PubMed ID: 11241319
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.
Kamataki T; Fujieda M; Kiyotani K; Iwano S; Kunitoh H
Biochem Biophys Res Commun; 2005 Dec; 338(1):306-10. PubMed ID: 16176798
[TBL] [Abstract][Full Text] [Related]
13. The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant.
Wang SL; He XY; Shen J; Wang JS; Hong JY
Toxicol Sci; 2006 Nov; 94(1):38-45. PubMed ID: 16917071
[TBL] [Abstract][Full Text] [Related]
14. Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13.
Jalas JR; Ding X; Murphy SE
Drug Metab Dispos; 2003 Oct; 31(10):1199-202. PubMed ID: 12975327
[TBL] [Abstract][Full Text] [Related]
15. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
[TBL] [Abstract][Full Text] [Related]
16. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies.
Liu T; Xie CB; Ma WJ; Chen WQ
Environ Mol Mutagen; 2013 Mar; 54(2):133-40. PubMed ID: 23203414
[TBL] [Abstract][Full Text] [Related]
17. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China.
Song N; Tan W; Xing D; Lin D
Carcinogenesis; 2001 Jan; 22(1):11-6. PubMed ID: 11159735
[TBL] [Abstract][Full Text] [Related]
18. [How I was enticed into molecular toxicology].
Kamataki T
Yakugaku Zasshi; 2006 Dec; 126(12):1309-18. PubMed ID: 17139156
[TBL] [Abstract][Full Text] [Related]
19. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking.
Schneider J; Bernges U; Philipp M; Woitowitz HJ
Cancer Lett; 2004 May; 208(1):65-74. PubMed ID: 15105047
[TBL] [Abstract][Full Text] [Related]
20. A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking.
Liang G; Miao X; Zhou Y; Tan W; Lin D
Carcinogenesis; 2004 May; 25(5):773-8. PubMed ID: 14688021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
